The settlement pact paves the way for the introduction of Yesafili, a proposed biosimilar to Eeylea (aflibercept) injection, in the Canadian market, Biocon Biologics said in a regulatory filing.
Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada
